; (B) limit the transfer and sale of any cannabis manufactured pursuant to this section— (i) to researchers who are registered under this Act to conduct research with controlled substances in schedule I; and (ii) for purposes of use in preclinical research or in a clinical investigation pursuant to an investigational new drug exemption under 505(i) of the Federal Food, Drug, and Cosmetic Act; (C) transfer or sell any cannabis manufactured pursuant to this section only with prior, written consent for the transfer or sale by the Attorney General; (D) have completed the application and review process under subsection (a) for the bulk manufacture of controlled substances in schedule I; (E) have established and begun operation of a process for storage and handling of controlled substances in schedule I, including for inventory control and monitoring security; (F) have the ability to provide at least 10 unique plant cultivars to ensure plant diversity and scale up to produce bulk plant material on an uninterrupted basis sufficient to supply forecasted demand; (G) be licensed, by each State in which the manufacturer conducts its operations pursuant to this subsection, to manufacture cannabis; (H) have completed a criminal background check for all personnel involved in the operations of the manufacturer pursuant to this subsection to confirm that such personnel have no conviction for a felony or drug-related misdemeanor; (I) have a letter of reference affirming the manufacturer’s good standing from each of the applicable State health care and law enforcement authorities in each jurisdiction of the manufacturer’s operations pursuant to this subsection